Comparative Pharmacology
Head-to-head clinical analysis: CYCLOCORT versus FOAMICON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOCORT versus FOAMICON.
CYCLOCORT vs FOAMICON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin synthesis.
FOAMICON is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
Apply a thin film topically to affected area twice daily (morning and evening). Not for ophthalmic use.
Adults: 200 mg orally once daily, with or without food.
None Documented
None Documented
3.5 hours (terminal); clinical effect duration longer due to tissue binding.
Terminal elimination half-life 12-15 hours; clinically, steady-state achieved in ~3 days.
Primarily hepatic metabolism; inactive metabolites excreted renally (<1% unchanged) and in feces (biliary).
Primarily renal (65% unchanged, 15% as inactive metabolites); biliary/fecal 20%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid